Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 197 participants.
Also called NCT01313572
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 197 participants
- Registry
-
NCT01313572
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Belgium, Brazil, Netherlands
- Registry status
- Terminated
Technical summary
Registry record NCT01313572. Randomized; triple masking; primary purpose diagnostic. Start 2011-08 (registry gives no type); primary completion 2012-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
- Acronym
- ASPECT2
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Apadenoson SPECT-MPI
- Intervention (Drug)
- Adenosine SPECT-MPI
- Lead sponsor
- Forest Laboratories
- Collaborator
- PPD Development, LP
Record details
- Record id
cardio:ct-nct01313572- Content hash
7247652d64087c943c40ffe557bb2d521df2cdbf7cef162dd1b97e5f89ff0015